Want to see JP:4569 full AI Analyst Report?
KYORIN Pharmaceutical Co.,Ltd. (4569) AI Stock Analysis
KYORIN Pharmaceutical Co.,Ltd.
(TSE/TYO:4569)
The score is held back primarily by weakened FY2026 profitability and an inconsistent multi-year free-cash-flow profile, despite a conservatively financed balance sheet. Technicals add further pressure as the stock trades below key moving averages with negative MACD. Valuation is mixed: a strong dividend yield helps, but a high P/E limits upside support.
KYORIN Pharmaceutical Co.,Ltd. (4569) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 65.83B
- Dividend Yield
- 4.28%
- Average Volume (3M)
- 221.64K
- Price to Earnings (P/E)
- 30.7
- Beta (1Y)
- 0.47
- Revenue Growth
- -4.71%
- EPS Growth
- -78.91%
- Country
- Japan
- Employees
- 1,982
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
KYORIN Pharmaceutical Co.,Ltd. Business Overview & Revenue Model
Company Description
Based in Tokyo, Japan, and founded in 1923, KYORIN Holdings, Inc. is a pharmaceutical enterprise engaged in the discovery, development, production, and worldwide distribution of both innovative prescription drugs and generic equivalents. Its diverse...
How the Company Makes Money
KYORIN Pharmaceutical primarily makes money from (1) sales of prescription pharmaceuticals and (2) income tied to out-licensing/commercialization arrangements for certain products. 1) Prescription drug sales (core revenue stream) - Product revenue: T...
KYORIN Pharmaceutical Co.,Ltd. Financial Statement Overview
Summary
Balance sheet strength and low leverage support resilience (debt-to-equity ~0.17), but FY2026 showed a clear profitability reset (gross margin down to ~40.9%, net margin to ~2.7%) and cash-flow quality remains mixed with historically volatile free cash flow despite turning positive in FY2026.
Income Statement
54NeutralBalance Sheet
78PositiveCash Flow
45Neutral| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 125.68B | 126.26B | 130.09B | 119.53B | 113.27B | 105.53B |
| Gross Profit | 50.53B | 51.61B | 59.51B | 51.62B | 50.16B | 49.44B |
| EBITDA | 6.83B | 8.22B | 17.15B | 10.52B | 8.96B | 8.72B |
| Net Income | 2.17B | 3.45B | 9.09B | 5.47B | 4.72B | 3.93B |
Balance Sheet | ||||||
| Total Assets | 188.61B | 195.46B | 193.62B | 177.63B | 176.04B | 171.92B |
| Cash, Cash Equivalents and Short-Term Investments | 16.95B | 15.08B | 16.51B | 13.98B | 19.39B | 27.49B |
| Total Debt | 23.24B | 23.79B | 28.44B | 20.95B | 21.28B | 21.62B |
| Total Liabilities | 48.30B | 53.02B | 57.33B | 46.89B | 50.58B | 47.41B |
| Stockholders Equity | 140.30B | 142.43B | 136.28B | 130.74B | 125.46B | 124.51B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 2.52B | -2.19B | -4.23B | -4.32B | 3.90B |
| Operating Cash Flow | 0 | 6.38B | 3.51B | 1.55B | 2.01B | 6.35B |
| Investing Cash Flow | 0 | -1.64B | -6.32B | -3.19B | -6.28B | -2.56B |
| Financing Cash Flow | 0 | -7.96B | 3.95B | -3.35B | -3.36B | -4.11B |
KYORIN Pharmaceutical Co.,Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4569, the sentiment is Negative. The current price of 1098.00 is above the 20-day moving average (MA) of 1095.90, below the 50-day MA of 1113.70, and below the 200-day MA of 1333.00, indicating a neutral trend. The MACD of 0.10 indicates Negative momentum. The RSI at 47.73 is Neutral, neither overbought nor oversold. The STOCH value of 32.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4569.
KYORIN Pharmaceutical Co.,Ltd. Peers Comparison
Overall Rating
JP:451673Outperform
JP:453468Neutral
JP:452164.9Neutral
JP:454764Neutral
JP:455360Neutral- JP:456952Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:4516 | 73Outperform | JPY 226.17B | 7.41 | ― | 3.69% | 12.23% | 3.35% |
| JP:4534 | 68Neutral | JPY 111.10B | 13.25 | 6.64% | 2.52% | 14.72% | 52.55% |
| JP:4521 | 65Neutral | JPY 136.33B | 14.34 | 6.94% | 5.03% | -6.86% | -17.71% |
| JP:4547 | 64Neutral | JPY 152.97B | 11.54 | 6.31% | 5.46% | 5.87% | -21.24% |
| JP:4553 | 60Neutral | JPY 174.71B | 21.91 | 4.53% | 2.28% | 6.78% | -48.34% |
| JP:4569 | 52Neutral | JPY 58.22B | 30.69 | ― | 4.28% | -4.71% | -78.91% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4569 | KYORIN Pharmaceutical Co.,Ltd. | 1098.00 | -264.93 | -19.44% | |
| JP:4521 | Kaken Pharmaceutical Co | 3780.00 | 269.47 | 7.68% | |
| JP:4547 | Kissei Pharmaceutical Co | 3755.00 | -74.40 | -1.94% | |
| JP:4553 | Towa Pharmaceutical Co | 3515.00 | 784.45 | 28.73% | |
| JP:4534 | Mochida Pharmaceutical Co., Ltd. | 3275.00 | 258.34 | 8.56% | |
| JP:4516 | Nippon Shinyaku Co., Ltd. | 3357.00 | 173.07 | 5.44% |
KYORIN Pharmaceutical Co.,Ltd. Corporate Events
KYORIN to Promote World’s First Cream Treatment for Allergic Conjunctivitis in Partnership with Santen
KYORIN Pharmaceutical will begin promotion of Alesion eyelid cream 0.5%, a once-daily, long-acting treatment for allergic conjunctivitis, from August 17, 2026 under a joint marketing deal with Santen Pharmaceutical. Santen will handle manufacturing,...
KYORIN Pharmaceutical Details Q1 Results and Pipeline Outlook for FY2027
KYORIN Pharmaceutical Co., Ltd., a Japan-based drug manufacturer, specializes in developing and selling prescription pharmaceuticals while maintaining an active pipeline of medicines under development. The company’s operations encompass consoli...
KYORIN Pharmaceutical Warns of Profit Slump and Dividend Cut Despite Strong Balance Sheet
KYORIN Pharmaceutical reported consolidated net sales of ¥29.65 billion for the three months ended June 30, 2026, down 1.9% year on year, while operating profit plunged 59.3% to ¥964 million and profit attributable to owners of parent fell...
KYORIN, Santen Team Up to Expand Marketing of Novel Allergic Conjunctivitis Cream in Japan
KYORIN Pharmaceutical has entered a joint marketing agreement in Japan with ophthalmology specialist Santen Pharmaceutical for Alesion eyelid cream 0.5%, a long-acting treatment for allergic conjunctivitis. Under the deal, Santen will continue manufa...
KYORIN Pharmaceutical Keeps Annual Dividend Steady at ¥57 Per Share
KYORIN Pharmaceutical’s board has approved a year-end dividend of ¥37 per share for shareholders of record as of March 31, 2026, funded from retained earnings. Combined with an interim dividend of ¥20, this brings the total annual div...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 17, 2026